Eiger Biopharmaceuticals (NASDAQ:EIGR) Research Coverage Started at Ladenburg Thalmann Financial Services

Analysts at Ladenburg Thalmann Financial Services initiated coverage on shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) in a research report issued to clients and investors on Wednesday, January 3rd, Marketbeat Ratings reports. The firm set a “buy” rating and a $32.00 price target on the biotechnology company’s stock. Ladenburg Thalmann Financial Services’ target price suggests a potential upside of 100.00% from the stock’s current price.

EIGR has been the topic of several other research reports. Oppenheimer set a $34.00 price target on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research upgraded Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Monday, October 16th. ValuEngine upgraded Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Roth Capital started coverage on Eiger Biopharmaceuticals in a research report on Thursday, October 19th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Wedbush reaffirmed a “buy” rating on shares of Eiger Biopharmaceuticals in a research report on Wednesday, October 25th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $30.63.

Eiger Biopharmaceuticals (NASDAQ EIGR) traded up $0.65 during trading on Wednesday, hitting $16.00. The company had a trading volume of 205,450 shares, compared to its average volume of 173,961. The company has a debt-to-equity ratio of 1.19, a current ratio of 5.78 and a quick ratio of 5.78. The stock has a market cap of $168.26, a P/E ratio of -3.02 and a beta of 2.54. Eiger Biopharmaceuticals has a 52 week low of $6.10 and a 52 week high of $16.20.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.28) by $0.18. research analysts predict that Eiger Biopharmaceuticals will post -4.59 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in EIGR. Sphera Funds Management LTD. lifted its holdings in shares of Eiger Biopharmaceuticals by 35.0% during the 3rd quarter. Sphera Funds Management LTD. now owns 520,269 shares of the biotechnology company’s stock valued at $5,723,000 after buying an additional 134,968 shares during the period. P.A.W. Capital Corp bought a new position in shares of Eiger Biopharmaceuticals during the 3rd quarter valued at $880,000. Goldman Sachs Group Inc. bought a new position in shares of Eiger Biopharmaceuticals during the 2nd quarter valued at $272,000. Susquehanna International Group LLP bought a new position in shares of Eiger Biopharmaceuticals during the 2nd quarter valued at $114,000. Finally, OxFORD Asset Management LLP bought a new position in shares of Eiger Biopharmaceuticals during the 3rd quarter valued at $147,000. 47.06% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2018/01/12/ladenburg-thalmann-financial-services-initiates-coverage-on-eiger-biopharmaceuticals-eigr.html.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply